Strem Brian M. 4

What Happened
Brian M. Strem, President & CEO and director of Kiora Pharmaceuticals (KPRX), received equity awards on March 6, 2026: 16,733 restricted shares (award A) and a derivative award (option) covering 33,467 shares (award A). Both grants show an acquisition price of $0.00 in the Form 4 filing; no cash was paid for these awards.

Key Details

• Transaction date: 2026-03-06; Form 4 filed: 2026-03-10 (appears timely).
• Awards: 16,733 restricted shares (grant) and an option/derivative for 33,467 shares (grant). Acquisition price reported as $0.00 for both.
• Vesting: Restricted shares vest 1/3 on each of April 1, 2027, 2028 and 2029 (F1). The option vests 1/3 on April 1, 2027, with the remainder vesting monthly over the next two years (F2), all subject to continuous service.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Transaction code: A = Award/Grant. These are grants, not open-market purchases or sales.

Context
These entries reflect equity compensation (restricted stock and an option grant) under Kiora’s 2024 Equity Incentive Plan and generally align with standard executive compensation practices tying awards to future service/vesting. Because these are grants (not purchases or sales), they do not represent an immediate cash investment or disposition by the insider.